While no clinical trials directly targeting CCR10+ TRM cells have yet been registered, current single-cell evidence supports their importance in SLE skin pathology and points to CCR10-mediated skin-homing pathways as candidate therapeutic targets. The gene discussed is CCR10; the disease is systemic lupus erythematosus.